Related Experiment Video
Updated: Jan 24, 2026

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
Published on: March 25, 2022
Precision medicine in primary biliary cholangitis
Vincenzo Ronca1, Alessio Gerussi1, Laura Cristoferi1
1Division of Gastroenterology and Center for Autoimmune Liver Diseases, San Gerardo Hospital, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Abstract:
For many years the one-size-fits-all approach has been the only one available to manage patients affected by primary biliary cholangitis. The introduction of obeticholic acid in 2016 as a second-line treatment, together with the creation and validation of several biochemically based scores to stratify the risk of progressive disease, has opened up the need to redefine clinical practice by changing the actual paradigm. The precision medicine initiative is a model of patient-centered health care that aims to improve medicine based on genotypic and molecular characteristics that correlate to specific phenotypic, individual characteristics. In summary, the aim of the precision medicine is to define the right treatment for the right person at the right time. The availability of a second-line disease-modifying drug and new molecules in phase 2 or 3 trials makes this an exciting time for the precision medicine initiative in primary biliary cholangitis. In this review we describe the current risk stratification tools and we track a possible path towards the application of precision medicine in clinical daily life.
Insights
Precision medicine offers personalized treatment for primary biliary cholangitis (PBC), moving beyond one-size-fits-all care. This approach utilizes patient-specific characteristics for optimal therapeutic strategies.
Area of Science:
- Hepatology and Gastroenterology
- Translational Medicine
- Pharmacogenomics
Background:
- Primary biliary cholangitis (PBC) management historically relied on a uniform approach.
- Recent advancements include second-line therapies like obeticholic acid and risk stratification scores.
- A paradigm shift towards personalized medicine is emerging for PBC treatment.
Purpose of the Study:
- To review current risk stratification tools for primary biliary cholangitis.
- To explore the application of precision medicine in managing PBC.
- To outline a pathway for integrating precision medicine into clinical practice.
Main Methods:
- Literature review of clinical practice guidelines and research on PBC management.
- Analysis of existing risk stratification scores and their biochemical basis.
- Discussion of the principles and potential of precision medicine in PBC.
Main Results:
- Obeticholic acid represents a significant advancement in second-line PBC treatment.
- Biochemical risk scores aid in stratifying patients with progressive disease.
- Emerging drug candidates in late-stage trials further support personalized treatment strategies.
Conclusions:
- Precision medicine promises tailored treatments for PBC based on individual patient profiles.
- Integrating precision medicine requires leveraging risk stratification and novel therapeutic options.
- The future of PBC management involves a patient-centered approach for improved outcomes.
Related Concept Videos
Uncertainty in Measurement: Accuracy and Precision
Accuracy and Precision
Microorganisms in Medicine and Therapeutics
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Primary Active Transport
Primary and Secondary Growth in Roots and Shoots

